NASDAQ:BMRN

Biomarin Pharmaceutical Stock News

etoro logo Buy BMRN
*Your capital is at risk
$60.02
-0.560 (-0.92%)
At Close: Jul 31, 2026
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV)...
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F
Inventiva SA has filed proposed terms for a U.S. IPO of $102 million.
BioMarin Pharmaceutical (NASDAQ:BMRN) had its target price boosted by equities research analysts at Citigroup from $105.00 to $148.00 in a research note issued on Monday, The Fly reports. The firm cur
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bristol Myers
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) AbbVie Inc (NYSE: ABBV) ADC...
A select group of stocks rose in the second quarter and for all of 2020.
The following is a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) * ADC Therapeutics SA (NYSE: ADCT) * Altim
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) ADC Therapeutics SA (...
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the promotions of Brian R. Mueller to Executive Vice President, Chief Financial Officer and of Andrea L. Acosta to Group Vice President, Chi
SAN RAFAEL, Calif., June 29, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the promotions of Brian R. Mueller to Executive Vice President, Chief Financial Officer an

Inventiva SA Starts U.S. IPO Rollout

03:52pm, Friday, 26'th Jun 2020
Inventiva SA has filed to raise $90 million in a U.S. IPO. The firm is advancing a pipeline of treatment candidates for NASH, MPS and other diseases. IVA is pre
Canaccord Genuity analyst Michelle Gilson reiterated a Buy rating on Stoke Therapeutics (STOK – Research Report) today and set a
Con motivo del Día Mundial de la Fenilcetonuria o PKU que se celebra el 28 de junio, la...
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE